10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2011 | |||
STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Cash flows from operating activities | |||
| Net loss | $ (221,760) | (104,468) | (67,830) |
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities | |||
| Depreciation and amortization | 31,082 | 19,687 | 14,247 |
| Non-cash compensation expense | 56,094 | 39,897 | 31,259 |
| Other non-cash charges and expenses, net | 10,366 | 3,171 | 2,238 |
| Changes in assets and liabilities | |||
| Increase in Sanofi and trade accounts receivable | (21,118) | (17,518) | (30,494) |
| Increase in prepaid expenses and other assets | (6,033) | (7,303) | (4,436) |
| (Decrease) increase in deferred revenue | (40,329) | 158,151 | (27,497) |
| Increase in accounts payable, accrued expenses, and other liabilities | 50,016 | 7,605 | 12,577 |
| Total adjustments | 80,078 | 203,690 | (2,106) |
| Net cash (used in) provided by operating activities | (141,682) | 99,222 | (69,936) |
| Cash flows from investing activities | |||
| Purchases of marketable securities | (240,391) | (605,124) | (199,997) |
| Sales or maturities of marketable securities | 426,356 | 273,723 | 295,117 |
| (Increase) decrease in restricted cash and marketable securities | (277) | (5,941) | 50 |
| Capital expenditures | (57,217) | (99,689) | (97,318) |
| Net cash provided by (used in) investing activities | 128,471 | (437,031) | (2,148) |
| Cash flows from financing activities | |||
| Proceeds in connection with facility lease obligation | 0 | 47,544 | 23,640 |
| Payments in connection with facility lease obligation | (674) | (924) | (875) |
| Payments in connection with capital lease obligation | (993) | (104) | 0 |
| Proceeds in connection with issuance of convertible notes, net of debt issuance costs | 391,107 | 0 | 0 |
| Proceeds in connection with issuance of warrants | 93,800 | 0 | 0 |
| Payment in connection with purchase of convertible note hedges | (117,500) | 0 | 0 |
| Net proceeds in connection with issuance of Common Stock | 18,509 | 196,790 | 8,598 |
| Net cash provided by financing activities | 384,249 | 243,306 | 31,363 |
| Net increase (decrease) in cash and cash equivalents | 371,038 | (94,503) | (40,721) |
| Cash and cash equivalents at beginning of period | 112,572 | 207,075 | |
| Cash and cash equivalents at end of period | 483,610 | 112,572 | 207,075 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | 14,725 | 12,737 | 2,525 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |